4 completed, 2 active not recruiting, 1 recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Elebsiran: new trials by email Literature Review of Elebsiran trials Research Report on Elebsiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) BRII-179, BRII-835 (VIR-2218), PEG-IFNα - Chronic Hepatitis B Virus (HBV) Infection | Phase 2 | Recruiting | Brii Biosciences Limited | 250 | 2024-10-31 | 2026-10-22 |
| Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) BRII-179, BRII-835 (VIR-2218), PEG-IFNα - For Treatment of Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 150 | 2024-08-06 | 2026-10-21 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 33 | 2023-05-10 | 2026-02-09 |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. VIR-2218, VIR-3434, NRTI - Hepatitis D, Chronic | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 95 | 2022-09-17 | 2026-06-26 |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection VIR-2218, VIR-3434, PEG-IFNα - Hepatitis B, Chronic | Phase 2 | Completed | Vir Biotechnology, Inc. | 244 | 2021-07-11 | 2026-04-23 |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection VIR-2218, pegylated interferon-alfa 2a - Chronic Hepatitis B | Phase 2 | Completed | Vir Biotechnology, Inc. | 84 | 2020-07-03 | 2026-04-16 |
Hepatitis (5) · Hepatitis B (4) · Hepatitis B, Chronic (4) · Hepatitis D (2) · Hepatitis D, Chronic (2) · Digestive System Diseases (1) · Infections (1) · Liver Diseases (1)
Vir Biotechnology, Inc. (5) · Brii Biosciences Limited (2)
Moldova (4) · Romania (4) · United Kingdom (4) · France (3) · Germany (3) · Hong Kong (3) · New Zealand (3) · South Korea (3) · Bulgaria (2) · China (2) · Malaysia (2) · Netherlands (2) · Ukraine (2) · Australia (1) · Belgium (1)